Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2022-01-05 00:00:00 ET · period of report 2022-01-04 · accession 0001209191-22-001700 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-05 | 2022-01-04 | CCCC | Crystal Adam | Chief Medical Off | M - OptEx | $6.49 | +15.0K | 30.0K | +100% | +$97.3K |
| DM | 2022-01-05 | 2022-01-04 | CCCC | Crystal Adam | Chief Medical Off | S - Sale+OE | $31.67 | -15.0K | 16.1K | -48% | -$475.0K |
| D | 2022-01-05 | 2022-01-04 | CCCC | Crystal Adam | Chief Medical Off | M - OptEx | $0.00 | -15.0K | 112.3K | -12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-04 | M | A | 15,000 | $6.49 | 30,000 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-04 | S | D | 1,054 | $32.66 | 15,000 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 3 | Common | Common Stock | 2022-01-04 | S | D | 13,946 | $31.59 | 16,054 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-01-04 | M | D | 15,000 | $0.00 | 112,292 | D | $6.49 · — to 2029-04-08 | 15,000 Common Stock | (F4) 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. |